Catalyst
Slingshot members are tracking this event:
Celgene (CELG) Expects Phase 3 RADIANCE Confirmatory Trial Data in Q2 Evaluating Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 22, 2017
Occurred Source:
http://ir.celgene.com/releasedetail.cfm?ReleaseID=1027283
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Confirmatory Trial, Ozanimod, Oral, Relapsing Multiple Sclerosis, Radiance
